175 related articles for article (PubMed ID: 29563139)
1. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
Zhang G; Wu LW; Mender I; Barzily-Rokni M; Hammond MR; Ope O; Cheng C; Vasilopoulos T; Randell S; Sadek N; Beroard A; Xiao M; Tian T; Tan J; Saeed U; Sugarman E; Krepler C; Brafford P; Sproesser K; Murugan S; Somasundaram R; Garman B; Wubbenhorst B; Woo J; Yin X; Liu Q; Frederick DT; Miao B; Xu W; Karakousis GC; Xu X; Schuchter LM; Mitchell TC; Kwong LN; Amaravadi RK; Lu Y; Boland GM; Wei Z; Nathanson K; Herbig U; Mills GB; Flaherty KT; Herlyn M; Shay JW
Clin Cancer Res; 2018 Oct; 24(19):4771-4784. PubMed ID: 29563139
[No Abstract] [Full Text] [Related]
2. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors.
Sengupta S; Sobo M; Lee K; Senthil Kumar S; White AR; Mender I; Fuller C; Chow LML; Fouladi M; Shay JW; Drissi R
Mol Cancer Ther; 2018 Jul; 17(7):1504-1514. PubMed ID: 29654065
[TBL] [Abstract][Full Text] [Related]
3. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.
Mender I; Gryaznov S; Dikmen ZG; Wright WE; Shay JW
Cancer Discov; 2015 Jan; 5(1):82-95. PubMed ID: 25516420
[TBL] [Abstract][Full Text] [Related]
4. Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity.
Mender I; Zhang A; Ren Z; Han C; Deng Y; Siteni S; Li H; Zhu J; Vemula A; Shay JW; Fu YX
Cancer Cell; 2020 Sep; 38(3):400-411.e6. PubMed ID: 32619407
[TBL] [Abstract][Full Text] [Related]
5. Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.
Mender I; LaRanger R; Luitel K; Peyton M; Girard L; Lai TP; Batten K; Cornelius C; Dalvi MP; Ramirez M; Du W; Wu LF; Altschuler SJ; Brekken R; Martinez ED; Minna JD; Wright WE; Shay JW
Neoplasia; 2018 Aug; 20(8):826-837. PubMed ID: 30015158
[TBL] [Abstract][Full Text] [Related]
6.
Mender I; Batten K; Peyton M; Vemula A; Cornelius C; Girard L; Gao B; Minna JD; Shay JW
Cancer Res; 2020 Mar; 80(5):929-936. PubMed ID: 31948943
[TBL] [Abstract][Full Text] [Related]
7. Short and dysfunctional telomeres protect from allergen-induced airway inflammation.
Piñeiro-Hermida S; Martínez P; Blasco MA
Aging Cell; 2021 May; 20(5):e13352. PubMed ID: 33942458
[TBL] [Abstract][Full Text] [Related]
8. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer.
Eglenen-Polat B; Kowash RR; Huang HC; Siteni S; Zhu M; Chen K; Bender ME; Mender I; Stastny V; Drapkin BJ; Raj P; Minna JD; Xu L; Shay JW; Akbay EA
Nat Commun; 2024 Jan; 15(1):672. PubMed ID: 38253555
[TBL] [Abstract][Full Text] [Related]
9. Turning telomerase into a Jekyll and Hyde case?
Wellinger RJ
Cancer Discov; 2015 Jan; 5(1):19-21. PubMed ID: 25583799
[TBL] [Abstract][Full Text] [Related]
10. A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells.
Mender I; Gryaznov S; Shay JW
Oncoscience; 2015; 2(8):693-5. PubMed ID: 26425659
[TBL] [Abstract][Full Text] [Related]
11. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
[TBL] [Abstract][Full Text] [Related]
12. Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.
Reyes-Uribe P; Adrianzen-Ruesta MP; Deng Z; Echevarria-Vargas I; Mender I; Saheb S; Liu Q; Altieri DC; Murphy ME; Shay JW; Lieberman PM; Villanueva J
Oncogene; 2018 Jul; 37(30):4058-4072. PubMed ID: 29695835
[TBL] [Abstract][Full Text] [Related]
13. A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.
Yu S; Wei S; Savani M; Lin X; Du K; Mender I; Siteni S; Vasilopoulos T; Reitman ZJ; Ku Y; Wu D; Liu H; Tian M; Chen Y; Labrie M; Charbonneau CM; Sugarman E; Bowie M; Hariharan S; Waitkus M; Jiang W; McLendon RE; Pan E; Khasraw M; Walsh KM; Lu Y; Herlyn M; Mills G; Herbig U; Wei Z; Keir ST; Flaherty K; Liu L; Wu K; Shay JW; Abdullah K; Zhang G; Ashley DM
Clin Cancer Res; 2021 Dec; 27(24):6800-6814. PubMed ID: 34593527
[TBL] [Abstract][Full Text] [Related]
14. Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.
Fischer-Mertens J; Otte F; Roderwieser A; Rosswog C; Kahlert Y; Werr L; Hellmann AM; Berding M; Chiu B; Bartenhagen C; Fischer M
Cell Oncol (Dordr); 2022 Oct; 45(5):991-1003. PubMed ID: 35953764
[TBL] [Abstract][Full Text] [Related]
15. Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma.
Mender I; Siteni S; Barron S; Flusche AM; Kubota N; Yu C; Cornelius C; Tedone E; Maziveyi M; Grichuk A; Venkateswaran N; Conacci-Sorrell M; Hoshida Y; Kang R; Tang D; Gryaznov S; Shay JW
Mol Cancer Ther; 2023 Jun; 22(6):737-750. PubMed ID: 37070671
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the promoter of the telomerase gene
Chiba K; Lorbeer FK; Shain AH; McSwiggen DT; Schruf E; Oh A; Ryu J; Darzacq X; Bastian BC; Hockemeyer D
Science; 2017 Sep; 357(6358):1416-1420. PubMed ID: 28818973
[No Abstract] [Full Text] [Related]
17. The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma.
Yu J; Yu J; Wu X; Guo Q; Yin T; Cheng Z; Dai J; Kong Y; Guo J
Clin Sci (Lond); 2020 Jan; 134(2):193-205. PubMed ID: 31919521
[TBL] [Abstract][Full Text] [Related]
18.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
19. Highly Aggressive Metastatic Melanoma Cells Unable to Maintain Telomere Length.
Viceconte N; Dheur MS; Majerova E; Pierreux CE; Baurain JF; van Baren N; Decottignies A
Cell Rep; 2017 Jun; 19(12):2529-2543. PubMed ID: 28636941
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
Andrés-Lencina JJ; Rachakonda S; García-Casado Z; Srinivas N; Skorokhod A; Requena C; Soriano V; Kumar R; Nagore E
Int J Cancer; 2019 Mar; 144(5):1027-1036. PubMed ID: 30070694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
